{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028809","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.701920+00:00","generated_at":"2026-06-05T08:50:46.461159+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039","bullets":["Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.","The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.","Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.","Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028809","json":"https://secwatch.observer/filing/0001104659-24-028809.json","markdown":"https://secwatch.observer/filing/0001104659-24-028809.md","text":"https://secwatch.observer/filing/0001104659-24-028809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/0001104659-24-028809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/tm247495d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:50:46.461159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}